Source: Pharamceutical Technology

Prilenia: Pridopidine hydrochloride by Prilenia Therapeutics Development for Huntington Disease: Likelihood of Approval

Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease.

Read full article »
Prilenia's Competitors | Prilenia's News | Prilenia's Financials
Stay up-to-date with the latest news on Prilenia
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Michael R. Hayden's photo - CEO of Prilenia

CEO

Michael R. Hayden

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on Prilenia